The Claim
In patients with established atherosclerotic cardiovascular disease, lowering LDL cholesterol to below 55 mg/dL reduces the risk of major adverse cardiovascular events by 33% over 3 years, with no increase in adverse events compared to higher LDL cholesterol targets.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with known heart disease, lowering LDL cholesterol to under 55 mg/dL reduces the chance of heart attacks, strokes, or death by 33% within three years, and does not increase the rate of side effects compared to higher LDL targets.
See the scientific wording
In patients with established atherosclerotic cardiovascular disease, lowering LDL cholesterol to below 55 mg/dL reduces the risk of major adverse cardiovascular events by 33% over 3 years, and this benefit is achieved without increasing safety risks, as demonstrated by comparable adverse event rates to higher LDL targets.
When LDL cholesterol drops below 55 mg/dL, less cholesterol enters the artery walls, causing fatty plaques to shrink and become less inflamed. This makes the plaques tougher and less likely to burst, which prevents blood clots that cause heart attacks and strokes.
What the research says
1 studyFor heart disease patients with fatty, unstable plaques in their arteries, lowering LDL cholesterol below 55 mg/dL greatly reduces the chance of heart attacks or strokes. But this benefit doesn’t seem to happen for everyone — only those with these specific dangerous plaques.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.